Supplier of biotechnology instrumentation becomes sole UK agent, and will actively promote microarray analysis and cell based screening systems
GRI, the supplier of biotechnology instrumentation, has signed a sole UK agency agreement with Axon Instruments.
The agreement permits GRI to actively promote Axon's microarray analysis and cell based screening systems through its molecular and cellular biology sales divisions respectively.
GRI says that the addition of Axon Instruments to its product portfolio ensures that the UK biotech industry has access to the latest in cutting edge technology, backed by customer and product support unrivalled in today's market.
Axon Instruments's mission is to be the best-in-class developer and manufacturer of novel high-technology devices and software for drug discovery. GRI's commitment to providing UK biotechnology with the highest quality instrumentation available ensures that the Axon product line will receive the highest level of service and promotion from their specialist sales divisions.
GRI Molecular Biology will have responsibility for distribution of Axon's microarray analysis systems including scanners and analysis software for DNA, protein and other microarrays.
GRI Cellular Biology will concentrate on the cell-based screening systems, which include cell-based pharmaceutical screening using high-resolution fluorescence imaging and electrophysiology (patch and voltage clamp) instruments.
